Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.73 |
| ▸ | DRD3 | P35462 | 16/20 | 0.73 |
| ▸ | NAMPT | P43490 | 2/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074410 | 1.00 | DRD2 (0.73) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL3073890 | 0.99 | DRD2 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL3086811 | 0.99 | DRD2 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL82749 | 0.99 | DRD2 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL82104 | 0.99 | DRD2 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL3089642 | 0.94 | DRD2 (0.65) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL3090272 | 0.94 | DRD2 (0.65) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL6266296 | 0.87 | DRD3 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL6266293 | 0.87 | DRD3 (0.72) | DRD2DRD3NAMPTDRD4HTR1A | |
| SCHEMBL83341 | 0.86 | DRD2 (0.59) | DRD2DRD3NAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-1060163-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | DRD2 4023/4885DRD3 4289/4885NAMPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.